Fax: (206) 667-2917
Article first published online: 29 JUN 2011
Copyright © 2011 American Cancer Society
Volume 118, Issue 2, pages 300–311, 15 January 2012
How to Cite
Radich, J. P. (2012), Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia . Cancer, 118: 300–311. doi: 10.1002/cncr.26280
See related articles:
I acknowledge StemScientific, funded by Bristol-Myers Squibb, for providing writing and editorial support for this article. Bristol-Myers Squibb did not influence the content of the article, nor did I receive any compensation, financial or otherwise, for authoring the article.
- Issue published online: 5 JAN 2012
- Article first published online: 29 JUN 2011
- Manuscript Accepted: 21 APR 2011
- Manuscript Revised: 14 APR 2011
- Manuscript Received: 2 DEC 2010
- chronic myeloid leukemia;
- cytogenetic response;
In patients with chronic myeloid leukemia (CML), the hallmark Philadelphia chromosome is the marker of disease that can be detected by conventional metaphase cytogenetics, fluorescence in situ hybridization, or polymerase chain reaction. The current “gold standard” of treatment response is cytogenetic response. Cytogenetic response to imatinib is strongly associated with disease progression and survival. Various strategies aimed at improving cytogenetic response have been explored, such as escalation of imatinib and switching to the newer breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene (BCR-ABL) inhibitors dasatinib and nilotinib. Data from recent randomized trials of dasatinib and nilotinib as first-line therapy of newly diagnosed chronic-phase CML suggest that these agents are more effective than imatinib in achieving 6-month and 12-month complete cytogenetic responses. However, it is still too early to know whether or not this early response will translate into a long-term survival advantage. In addition, more sensitive assays to detect residual disease also may be associated with improved long-term outcomes. The deepest measure of response—a complete molecular response—may help identify patients who can stop taking imatinib for the short term, although the long-term consequences of this strategy remain unknown. Cancer 2011;. © 2011 American Cancer Society.